GlassScriptPhysician profile
Amber Galownia
NPI 1629629753
$5,998.43
in general payments reported to CMS, 2019-2025
33 companies · $3,352 in 2025
The $3,352 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $175 · 2023: $1,237 · 2024: $1,100 · 2025: $3,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,001 · Consulting Fee: $1,430 · Travel and Lodging: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.38 |
| Consulting Fee | $1,430.00 |
| Travel and Lodging | $258.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,696.61 | 2022-2025 | Epclusa |
| Abbvie INC. | $815.45 | 2021-2025 | |
| Indivior INC. | $303.49 | 2022-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.70 | 2025 | Caplyta |
| Braeburn INC. | $200.48 | 2024-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $199.77 | 2023-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $160.76 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $157.69 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corcept Therapeutics | $154.32 | 2025 | Korlym |
| Lilly USA, LLC | $146.83 | 2023-2025 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $115.55 | 2024-2025 | |
| Alkermes, INC. | $90.75 | 2022-2024 | Vivitrol, Vivitrol |
| Ethicon US, LLC | $78.08 | 2021 | |
| Exact Sciences Corporation | $71.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $69.35 | 2024 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $65.09 | 2023-2024 | Breztri, Airsupra |
| Ironshore Pharmaceuticals INC. | $53.02 | 2023 | Jornay Pm |
| Edwards Lifesciences Corporation | $50.30 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Regeneron Healthcare Solutions, INC. | $36.48 | 2025 | Dupixent |
| Xeris Pharmaceuticals, INC. | $36.01 | 2025 | Gvoke Hypopen |
| Almirall LLC | $35.56 | 2025 | Klisyri, Seysara |
| Organon LLC | $34.38 | 2023 | Nexplanon |
| Pfizer INC. | $33.28 | 2025 | |
| Neurelis, INC. | $26.02 | 2024 | Valtoco |
| Mylan Specialty L.P. | $22.73 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $22.66 | 2024 | Delstrigo, Pifeltro |
| Dexcom, INC. | $18.61 | 2023 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $17.37 | 2025 | Apretude |
| Novo Nordisk INC | $17.27 | 2024 | Wegovy |
| Tactile Systems Technology INC | $15.55 | 2024 | Entre Plus, Flexitouch Plus |
| Medtronic, INC. | $14.71 | 2025 | Inceptiv |
| Axsome Therapeutics, INC. | $14.43 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $13.83 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Galownia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.